KRAS: Druggable at Last.

doi:10.1093/oncolo/oyad014

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS: Druggable at Last.

The oncologist - 6 Apr 2023

Herzberg Benjamin O, Manji Gulam A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 36933199
DOI: 10.1093/oncolo/oyad014
PMCID: PMC10078900

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS: Druggable at Last.PMID 36933199Read ↗

Targeting KRAS: Good, But Is It Good Enough?Semantic proximity Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

Expanding the options for KRAS inhibition.Semantic proximity Read ↗

Targeting KRAS with reversible inhibitors.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

The case for eteplirsen: Paving the way for precision medicine.Semantic proximity Read ↗

Drug pipeline: 1Q12.Semantic proximity Read ↗

It Takes Two To Target: A Study in KRAS Dimerization.Semantic proximity Read ↗

Golodirsen: First ApprovalSemantic proximity Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.Semantic proximity Read ↗

From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.